These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31330801)

  • 1. The Role of a "Treat-to-Target" Approach in the Long-Term Renal Outcomes of Patients with Gout.
    Kim WJ; Song JS; Choi ST
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330801
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
    Pui K; Gow PJ; Dalbeth N
    J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study.
    Jing J; Kielstein JT; Schultheiss UT; Sitter T; Titze SI; Schaeffner ES; McAdams-DeMarco M; Kronenberg F; Eckardt KU; Köttgen A;
    Nephrol Dial Transplant; 2015 Apr; 30(4):613-21. PubMed ID: 25395390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
    Kim Y; Shin S; Kim K; Choi S; Lee K
    J Rheumatol; 2015 Nov; 42(11):2143-8. PubMed ID: 26428209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
    Mohammed E; Browne LD; Kumar A U A; Adeeb F; Fraser AD; Stack AG
    PLoS One; 2019; 14(1):e0210487. PubMed ID: 30682034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study.
    Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
    Rheumatology (Oxford); 2019 Mar; 58(3):410-417. PubMed ID: 30285127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
    Johnson RJ; Choi HK; Yeo AE; Lipsky PE
    Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a urate lowering regimen in primary gout.
    Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with initiation and persistence of urate-lowering therapy.
    Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
    Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.